目的 探究半乳糖凝集素-3(galectin-3,Gal-3)在肝细胞癌(hepatocellular carcinoma,HCC)中的表达及预后相关性,并通过虚拟筛选结合体外实验验证所获得的抑制剂,并初步阐明其作用机制。方法 通过癌症基因组图谱数据库和人类蛋白质图谱数据库分析Gal-3在HCC中的表达水平与预后相关性。使用Schrödinger软件对接TargetMol L4000化合物库筛选得到候选抑制剂。不同浓度抑制剂作用HCC细胞系24 h和48 h后,分别采用细胞计数试剂盒-8(Cell Counting Kit-8,CCK-8)、5-乙炔基-2′-脱氧尿苷(5-ethynyl-2′-deoxyuridine,EdU)和划痕实验检测细胞活力、增殖及迁移能力,并进行基因相关性分析。结果 HCC组织中Gal-3表达显著高于正常组织(P<0.05),且与患者生存率呈负相关(P<0.01)。虚拟筛选获得105个候选分子,最终选定丹酚酸B镁盐(magnesium lithospermate B,MLB)。体外实验表明,MLB显著抑制HCC细胞克隆形成、增殖和迁移。基因分析显示ADRA1A和ADRB2与Gal-3表达负相关(r=-0.26和-0.16,均P<0.01)。结论 Gal-3在HCC中高表达,并与不良预后相关。MLB通过靶向Gal-3抑制HCC增殖和迁移,可能经由上调ADRA1A和ADRB2表达,为HCC治疗提供新依据和候选药物。
Abstract
Objective To investigate the expression and prognostic relevance of galectin-3(Gal-3) in hepatocellular carcinoma (HCC), to identify Gal-3-targeting inhibitors through virtual screening followed by in vitro validation, and to preliminarily elucidate the underlying mechanisms. Methods Gal-3 expression and its association with prognosis in HCC were analyzed using The Cancer Genome Atlas (TCGA) and the Human Protein Atlas (HPA) databases. Candidate inhibitors were obtained by docking the TargetMol L4000 compound library using Schrödinger. HCC cell lines were treated with different concentrations of inhibitors for 24 h and 48 h. Cell viability, proliferation, and migration were assessed using Cell Counting Kit-8(CCK-8), 5-ethynyl-2′-deoxyuridine (EdU) incorporation, and wound-healing assays, respectively, followed by gene correlation analysis. Results Compared with normal liver tissues, Gal-3 expression was significantly increased in HCC tissues (P<0.05), and high Gal-3 expression was negatively associated with overall survival (P<0.01). Virtual screening yielded 105 candidate small molecules, and magnesium lithospermate B (MLB) was selected as the representative compound. In vitro assays confirmed that MLB significantly inhibited colony formation, proliferation, and migration of HCC cells. Differential expression and correlation analyses showed that ADRA1A and ADRB2 were negatively correlated with Gal-3 expression (r=-0.26 and -0.16, respectively; both P<0.01). Conclusion Gal-3 is highly expressed in HCC and is associated with poor prognosis. MLB may suppress HCC cell proliferation and migration by targeting Gal-3, potentially through upregulation of ADRA1A and ADRB2, providing experimental evidence and a candidate agent for Gal-3-targeted therapy for HCC.
关键词
肝细胞癌 /
半乳糖凝集素-3 /
小分子抑制剂 /
丹酚酸B镁盐 /
作用机制
Key words
hepatocellular carcinoma /
galectin-3 /
small molecule inhibitors /
magnesium lithospermate B /
mechanism of action
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] MCGLYNN KA, PETRICK JL, GROOPMAN JD.Liver cancer: progress and priorities[J]. Cancer Epidemiol Biomarkers Prev, 2024, 33(10): 1261-1272.
[2] SINGAL AG, KANWAL F, LLOVET JM.Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy[J]. Nat Rev Clin Oncol, 2023, 20(12): 864-884.
[3] RUMGAY H, ARNOLD M, FERLAY J, et al.Global burden of primary liver cancer in 2020 and predictions to 2040[J]. J Hepatol, 2022, 77(6): 1598-1606.
[4] KOKUDO N, KOKUDO T, HASEGAWA K.Role of liver resection for hepatocellular carcinoma with vascular invasion: emerging evidence from western countries[J]. Liver Cancer, 2021, 10(5): 404-406.
[5] REIG M, FORNER A, RIMASSA L, et al.BCLC strategy for: prognosis prediction and treatment recommendation: the 2022 update[J]. J Hepatol, 2022, 76(3): 681-693.
[6] WANG Y, DENG BC.Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers[J]. Cancer Metastasis Rev, 2023, 42(3): 629-652.
[7] NANGIA-MAKKER P, HOGAN V, BALAN V, et al.Chimeric galectin-3 and collagens: biomarkers and potential therapeutic targets in fibroproliferative diseases[J]. J Biol Chem, 2022, 298(12): 102622.
[8] BOUTIN L, DEPRET F, GAYAT E, et al, . Galectin-3 in kidney diseases: from an old protein to a new therapeutic target[J]. Int J Mol Sci, 2022, 23(6): 3124.
[9] PEDROSA LF, RAZ A, FABI JP.The complex biological effects of pectin: galectin-3 targeting as potential human health improvement?[J]. Biomolecules, 2022, 12(2): 289.
[10] SONG M, PAN Q, YANG J, et al.Galectin-3 favours tumour metastasis via the activation of β-catenin signalling in hepatocellular carcinoma[J]. Br J Cancer, 2020, 123(10): 1521-1534.
[11] CHOI MJ, YOU TM, JANG YJ.Galectin-3 plays an important role in BMP7-induced cementoblastic differentiation of human periodontal ligament cells by interacting with extracellular components[J]. Stem Cells Int, 2023, 2023: 5924286.
[12] SELENE II, OZEN M, PATEL RA.Hepatocellular carcinoma: advances in systemic therapy[J]. Semin Intervent Radiol, 2024, 41(1): 56-62.
[13] SINGAL AG, LLOVET JM, YARCHOAN M, et al.AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma[J]. Hepatology, 2023, 78(6): 1922-1965.
[14] FU Y, MACCIONI L, WANG XW,, et al. Alcohol-associated liver cancer[J]. Hepatology, 2024, 80(6): 1462-1479.
[15] KOSHY A.Evolving global etiology of hepatocellular carcinoma (HCC): insights and trends for 2024[J]. J Clin Exp Hepatol, 2025, 15(1): 102406.
[16] JANOTA B, SZYMANEK B.The influence of diet and its components on the development and prevention of hepatocellular carcinoma (HCC)[J]. Cancers (Basel), 2024, 16(5): 1030.
[17] CHENG TL, LIN ZY, LIAO KY, et al.Magnesium lithospermate B attenuates high-fat diet-induced muscle atrophy in C57BL/6J mice[J]. Nutrients, 2021, 14(1): 104.
[18] FAN C, QIN K, IROEBGU CD, et al.Magnesium lithospermate B enhances the potential of human-induced pluripotent stem cell-derived cardiomyocytes for myocardial repair[J]. Chin Med J (Engl), 2024, 137(15): 1857-1869.
[19] LIN L, SHEN D, SU Y, et al.Magnesium lithospermate B protects against ischemic AKI-to-CKD progression via regulating the KLF5/CDK1/Cyclin B1 pathway[J]. Phytomedicine, 2025, 142: 156765.
[20] ZUO XL, CHEN ZQ, WANG JF, et al.MiR-337-3p suppresses the proliferation and invasion of hepatocellular carcinoma cells through targeting JAK2[J]. Am J Cancer Res, 2018, 8(4): 662-674.
[21] REZENDE CP, MARTINS OLIVEIRA BRITO PK, PESSONI AM, et al. Altered expression of genes related to innate antifungal immunity in the absence of galectin-3[J]. Virulence, 2021, 12(1): 981-988.
基金
湖南省卫生健康高层次人才重大科研专项“Galectin-8调控cGAS-STING信号通路在ICC中的作用及机制研究”(R2023075); 国家级大学生创新创业训练计划支持项目“基于虚拟筛选的方法探究潜在的半乳糖凝集素3的小分子抑制剂及其对肝细胞癌增殖的影响”(202410542061); 湖南师范大学大型仪器设备开放基金资助项目“ATF6通过调控p38信号通路抑制肝内胆管癌进展的机制研究”(25CSY056); 湖南师范大学大型仪器设备开放基金资助项目 “Galectin-3通过调控整合素β1促进肝内胆管癌进展的作用及机制研究”(24CSY207)